TY  - CONF
AU  - Peplinski, Jana-Marie
AU  - Werner, Jan-Michael
AU  - Ceccon, Garry
AU  - Wollring, Michael
AU  - Stetter, Isabelle
AU  - Rosen, Jurij
AU  - Rosen, Elena
AU  - Kraft, Manuel
AU  - Fink, Gereon
AU  - Langen, Karl-Josef
AU  - Lohmann, Philipp
AU  - Galldiks, Norbert
TI  - IMG-61. Assessment of18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria
SN  - 1523-5866
M1  - FZJ-2026-01602
PY  - 2025
AB  - AbstractBACKGROUNDWe evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their ability to predict longer overall survival (OS) in patients with glioblastoma treated with bevacizumab-based regimens at relapse.PATIENTS AND METHODSThirty-eight adult patients with IDH-wildtype glioblastoma were identified from three previously published studies. All patients (i) received bevacizumab in combination with a second agent (irinotecan, lomustine, or nivolumab), (ii) underwent MRI- and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging at baseline and at a median time of 8 weeks (range, 4-12 weeks) after treatment initiation, and (iii) had available PET-derived parameters, i.e., metabolic tumor volume (MTV), maximum and mean tumor-to-brain ratios (TBRmax and TBRmean). A post-hoc analysis was performed to evaluate the predictive value of the PET RANO 1.0 criteria. In addition, ROC analyses were performed to define PET parameter thresholds for predicting an OS≥9 months. Furthermore, response prediction using the RANO 2.0 criteria for MRI was compared with the PET RANO 1.0 criteria.RESULTSAccording to the PET RANO 1.0 criteria, patients fulfilling the criterion Stable Disease (n=10), Partial Response (n=19), or Complete Response (n=1) had a significantly longer OS than patients with Progressive Disease (n=8) (9.0 vs. 4.0 months; P=0.001). Among the suggested thresholds by the PET RANO 1.0 criteria, only a MTV reduction ≥40% was significantly predictive of response (7.3 vs. 4.0 months; P=0.008). Optimal thresholds identified by ROC analysis differed from those proposed by the PET RANO 1.0 criteria. A reduction in MTV by ≥30% and in TBRmean by ≥4% were both predictive of longer OS (7.3 vs. 4.0 months; P=0.008, and 10.6 vs. 6.0 months; P=0.010, respectively). The RANO 2.0 criteria were less significant to predict a longer OS (9.0 vs. 6.0 months; P=0.015).CONCLUSIONPET RANO 1.0 criteria appear to be effective in predicting response to bevacizumab-based therapy in glioblastomas at relapse.
T2  - 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies
CY  - 20 Nov 2025 - 23 Nov 2025, Honolulu (USA)
Y2  - 20 Nov 2025 - 23 Nov 2025
M2  - Honolulu, USA
LB  - PUB:(DE-HGF)1
DO  - DOI:10.1093/neuonc/noaf201.1140
UR  - https://juser.fz-juelich.de/record/1053904
ER  -